Are you Dr. Mills?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Gordon Mills, MD is an obstetrician/gynecologist in Houston, Texas. He is currently licensed to practice medicine in Texas. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
University of AlbertaClass of 1977
Certifications & Licensure
TX State Medical License 1996 - 2018
Publications & Presentations
PubMed
- DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis.Wei Liu, Jun Li, Yitao Tang, Yining Zhao, Chaozhong Liu
Nature Communications. 2025-03-06 - Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations.Mei Luo, Jingwen Yang, Alejandro A Schäffer, Chengxuan Chen, Yuan Liu
Cancer Discovery. 2025-03-03 - Selective abrogation of S6K2 identifies lipid homeostasis as a survival vulnerability in MAPK inhibitor-resistant-mutant melanoma.Brittany Lipchick, Adam N Guterres, Hsin-Yi Chen, Delaine M Zundell, Segundo Del Aguila
Science Translational Medicine. 2025-02-05
Press Mentions
Pangea Biomed Begins Pilot Collaboration with the OHSU Knight Cancer Institute to Improve Cancer Therapy PrecisionOctober 24th, 2024- How OHSU's 'SMMART' Cancer Trial Helped Guide One Patient to Unconventional TreatmentsJune 17th, 2022
- The Topic of CancerJune 16th, 2022
- Join now to see all
Grant Support
- Systematic Characterization and Targeting of Neomorphic Drivers in CancerOREGON HEALTH & SCIENCE UNIVERSITY2023–2028
- The Cancer Proteome Atlas: an Integrated Bioinformatics Resource for Functional Cancer Proteomic DataUNIVERSITY OF TX MD ANDERSON CAN CTR2022–2027
- Mechanistic maps of adaptive responses to therapeutic stress to optimize combination therapies.OREGON HEALTH & SCIENCE UNIVERSITY2021–2026
- Biological Annotation Of TCGA DataNational Cancer Institute2012
- The Role Of Aberrant Splicing Of Evl1 In Ovarian Cancer PathophysiologyNational Cancer Institute2008–2012
- Role Of RAB25 And Its Effectors In Breast Cancer BioengenericsNational Cancer Institute2010–2011
- P4 - Pers. Therapy For High-Grade Ovarian Cancer: Targeting Pi3kness &BrcaneNational Cancer Institute2010–2011
- Modeling Response To P13K Targeted TherapiesNational Cancer Institute2010–2011
- Modeling Response To P13K Target TherapiesNational Cancer Institute2010–2011
- Predictors Of Resistance Dual Vegfr/Egfr Targeted Therapy Of Head And Neck CancerNational Cancer Institute2009–2011
- Integrative Pipeline For Analysis &Translational Application Of TCGA Data (GDAC)National Cancer Institute2009–2011
- Targeting The PI3K Pathway In Ovarian CancerNational Cancer Institute2008–2009
- P-3: Predictors Of Resistnace Todual Vegfr/Egfr Targeted Therapy Of H&N CancerNational Cancer Institute2008
- MMAC1/PTEN Tumor Suppressor And Breast CancerNational Cancer Institute1999–2003
- PI-3 Kinase Pathway In Ovarian CancerNational Cancer Institute2001–2002
- LPA In Initiation And Progression In Ovarian CancerNational Cancer Institute2001–2002
- Phosphatidylinositol Signaling In Ovarian Tumorigenesis, Prognosis &TherapyNational Cancer Institute1999–2002
- CD Signaling Through Emt/Itk Tyrosine KinaseNational Cancer Institute1997–2001
- Ovarian Cancer Activating Factor In Ovarian Cancer Initiation And ProgressionNational Cancer Institute1996–2000
- Putative Tumor Suppressor Ptp1c In Breast CancerNational Cancer Institute1996–1998
